Ocean Genomics
The Intelligent Transcriptome
Key Applications
Solutions Spanning Drug Discovery & Development for Every Major Therapeutic Area
AI-driven multi-omic analysis brings new light to old questions and delivers unprecedented insights in previously unexplored territory.
Computationally-driven insights transcend what’s possible with manual analysis.
Discovery
Identify targets and mine biomarkers
Pre-Clinical
Assess assets, determine MoA, explore PK/PD studies, mine signatures
Clinical
Stratify patients, identify new subgroups, model patient response
Trial Salvage
Identify responding subgroups and provide biomarkers and rationale
Back-Translation
Discover new insights to incorporate into future programs
Indication Expansion
Discover signatures of response to identify additional potential patients
Founded By
Leaders in Genomics, AI & Machine Learning, and Computational Biology
Carl Kingsford, Ph.D.
Rob Patro, Ph.D.
Eric Schultz
Our Team has Developed Many of the Most Advanced and Widely Used RNA-Seq Software Applications
Validated Extensively
Our computational methods are backed by 4000+ Citations
Used Globally
Software created by our founders has been downloaded > 350K times
By Leading Organizations
Users include Johns Hopkins, Harvard, Roche, Pfizer, and Novartis
Leverage Our Deep Capabilities in Computational Biology, Our Advanced Platforms, and Extensive Data and AI Models to Add Power to Your Program
Join The Team
Career
Opportunities
Ocean Genomics, Inc. is seeking a full time Senior Computational Biologist at its Hyattsville, MD location. The Senior Computational Biologist shall develop new, efficient accurate, methods for analyzing large...
Computational Biology
RecentNews
Ocean Genomics Announces Poster Acceptance at ASCO 2023 with Yale Cancer Center – Identifying Molecular Predictors and Immunomodulatory Role of Dual Checkpoint Inhibitors in Small Cell Lung Cancer
PITTSBURGH, Pa. — Ocean Genomics’ abstract for their AI-driven combined transcriptomic and genomic analysis titled “Molecular Predictors and Immunomodulatory Role of Dual Checkpoint Inhibitor Blockade
Accenture Invests in Ocean Genomics to Accelerate AI-driven Drug Discovery and the Development of Personalized Medicines
NEW YORK; Feb. 16 , 2023 – Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Ocean Genomics, a technology and AI company
Ocean Genomics Announces Poster Acceptance for Transcriptomic Analysis Identifying Novel Expression Biomarkers of Response in Pancreatic Cancer at AACR
PITTSBURGH, Pa. — Ocean Genomics’ abstract for their AI-driven transcriptome analysis titled “Novel Expression Biomarkers via Prediction of Response to FOLFIRINOX (FFX) Treatment for Pancreatic